Mental health biomarkers Polaris Genomics has developed a first-to-market genomic biomarker assay to identify PTSD risk, indicating a strong basis for selling biomarker-driven mental health diagnostics and personalized treatment approaches to defense, veterans, and high-stress professions.

Veteran and first responder focus As a veteran-owned business with a mission to support military service members, veterans, and high-risk occupations, target government agencies, VA healthcare programs, and defense contractors for collaboration on PTSD risk screening and trauma-related diagnostics.

Strategic partnerships Existing collaborations with Illumina Accelerator, Mount Sinai, and the Max Planck Institute of Psychiatry suggest a proven model for co-development and validation; leverage these networks to identify new academic, clinical, and industry partners nationwide.

Public health expansion The expanding focus from military to frontline workers and trauma-exposed communities opens opportunities in corporate wellness programs, emergency response agencies, and occupational health providers seeking objective biomarkers for mental health risk assessment.

Financial momentum Recent debt financing and grant-backed funding alongside revenue generation indicate growing credibility; approach investors and grant-funded healthcare initiatives to scale diagnostics programs and accelerate market penetration.